Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.
Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
Lim
S W
SW
Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia. slim1@mail.rah.sa.gov.au
Gillis
D
D
Smith
W
W
Hissaria
P
P
Greville
H
H
Peh
C A
CA
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D017079:Exercise Tolerance / Q000187:drug effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D011014:Pneumonia / Q000188:drug therapy* / Q000209:etiology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab